期刊
EUROPEAN THYROID JOURNAL
卷 12, 期 3, 页码 -出版社
BIOSCIENTIFICA LTD
DOI: 10.1530/ETJ-22-0227
关键词
advanced follicular thyroid carcinoma; GEMOX (gemcitabine plus oxaliplatin); multikinase inhibitors
This case report highlights the potential efficacy of GEMOX chemotherapy in patients with advanced follicular thyroid carcinoma resistant to multikinase inhibitors. The durable response to GEMOX significantly extended the overall survival of the patient.
Background: Treatment of advanced follicular thyroid carcinoma (FTC) is based primarily on indirect evidence obtained with multikinase inhibitors (MKI) in clinical trials in which papillary carcinomas represent the vast majority of cases. However, it should be noted that MKI have a non-negligible toxicity that may decrease the patient's quality of life. Conventional chemotherapy with GEMOX (gemcitabine plus oxaliplatin) is an off-label therapy, which seems to have some effectiveness in advanced differentiated thyroid carcinomas, with a good safety profile, although further studies are needed. Case report: We report a case of a metastatic FTC, resistant to several lines of therapy. However, with a durable response to GEMOX, the overall survival of our patient appears to have been extended significantly due to this chemotherapy.Conclusion: GEMOX may have a role in patients with thyroid cancer unresponsive to MKI.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据